Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23374659 | 0.91 | SLC18A3 (0.56) | SLC18A3DRD2CARM1PRMT6MEN1 | |
| SCHEMBL12768109 | 0.91 | SLC18A3 (0.56) | SLC18A3DRD2CARM1PRMT6MEN1 | |
| SCHEMBL12447397 | 0.91 | SLC18A3 (0.56) | SLC18A3DRD2CARM1PRMT6MEN1 | |
| SCHEMBL23374690 | 0.84 | SLC18A3 (0.49) | SLC18A3DRD2 | |
| SCHEMBL11063274 | 0.83 | SLC18A3 (0.60) | SLC18A3DRD2CARM1PRMT6MEN1 | |
| SCHEMBL18212456 | 0.83 | SLC18A3 (0.46) | SLC18A3DRD2CARM1PRMT6CCR5 | |
| SCHEMBL6247690 | 0.83 | SLC18A3 (0.57) | SLC18A3DRD2 | |
| SCHEMBL8104014 | 0.83 | DRD2 (0.68) | SLC18A3DRD2CARM1PRMT6MEN1 | |
| SCHEMBL23374714 | 0.81 | DRD2 (0.65) | SLC18A3DRD2KMT2ASIGMAR1 | |
| SCHEMBL23374534 | 0.81 | DRD2 (0.65) | SLC18A3DRD2KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-8153817-B2 | Synthesis of methyl nonactate derivatives | OHIO UNIVERSITY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153817-B2 | Synthesis of methyl nonactate derivatives | OHIO UNIVERSITY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100056779-A1 | SYNTHESIS OF METHYL NONACTATE DERIVATIVES | OHIO UNIVERSITY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056779-A1 | SYNTHESIS OF METHYL NONACTATE DERIVATIVES | OHIO UNIVERSITY (US) | 2010-03-04 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7452911-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-11-18 | — | — | US | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | SLC18A3 4634/4885DRD2 4824/4885CARM1 589/4885 |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | SLC18A3 1805/4885DRD2 352/4885CARM1 935/4885 |
| US-20100056779-A1 | SYNTHESIS OF METHYL NONACTATE DERIVATIVES | AZI2, TET3, TET1 | SLC18A3 3122/4885DRD2 613/4885CARM1 736/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | SLC18A3 4634/4885DRD2 4824/4885CARM1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.